Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $21.03 is 56.71% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 21.52||$ 32.20|
|Low:||$ 20.73||$ 13.42|
ETFs with EXEL as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|38%||Barron's 400 (BFOR)||-6.85 (-15.41%)|
|4.75%||First Trust Amex Biotech Index Fund (FBT)||-17.81 (-11.85%)|
|3.01%||Invesco Dynamic Biotech & Genome ETF (PBE)||-9.80 (-16.52%)|
|2.36%||Invesco Russell MidCap Pure Growth ETF (PXMG)||-4.40 (-8.51%)|
|1.86%||Invesco S&P Midcap 400 Pure Growth ETF (RFG)||-25.69 (-15.45%)|
|*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 days.|
Company Description (as filed with the SEC)
Item 1. Business Overview Exelixis, Inc. ("Exelixis," "we," "our" or "us") is a biotechnology company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since our founding in 1994, three products discovered at Exelixis have progressed through clinical development, received regulatory approval, and entered the marketplace. Two are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET: CABOMETYX® (cabozantinib) tablets approved for advanced renal cell carcinoma, or RCC, and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer, or MTC. The third product, COTELLIC® (cobimetinib) tablets, is a formulation of cobimetinib and is an inhibitor of MEK, marketed under a collaboration with Genentech, Inc. ... More ...
Nasdaq Official Price
Dec. 14, 2018
Dec. 14, 2018